Pediatric Dosing and Excipient Toxicity in a Neonate
A 3-week-old neonate (3.2 kg) is prescribed an oral liquid antibiotic for a respiratory infection. The only available formulation is a 250 mg/5 mL suspension containing 0.5% w/v sodium benzoate and 10% v/v ethanol as preservatives. The calculated dose is 40 mg/kg/day divided q12h. The pharmacist notes the infant is also receiving caffeine citrate for apnea of prematurity and has a total bilirubin of 12 mg/dL.
1. Calculate the daily dose and volume, then assess the excipient exposure (benzoate and ethanol) against acceptable limits.
Read the worked answer
Dose: 40 mg/kg/day × 3.2 kg = 128 mg/day, divided q12h = 64 mg per dose. Volume per dose: 64 mg / (250 mg/5 mL) = 1.28 mL; total 2.56 mL/day. Sodium benzoate 0.5% w/v = 5 mg/mL; 2.56 mL = 12.8 mg/day benzoate (4 mg/kg/day). Ethanol 10% v/v = 0.1 mL ethanol/mL; 2.56 mL = 0.256 mL ethanol ≈ 0.2 g (0.063 g/kg/day). The AAP/WHO limits for neonates: ethanol should be avoided; benzoate is a concern because it competes with bilirubin for albumin binding and can displace bilirubin in a jaundiced neonate (total bilirubin 12 mg/dL is significant). Both excipients are potentially unsafe in a neonate with hyperbilirubinemia.
2. What is the clinical risk of each excipient in this patient, and how should the pharmacist intervene?
Read the worked answer
Benzoate: displaces bilirubin from albumin, increasing free bilirubin and kernicterus risk - especially with bilirubin 12 mg/dL and a premature/neonatal CNS. Ethanol: neonatal hepatic metabolism is immature; ethanol can cause hypoglycemia, CNS depression, and competes with bilirubin metabolism. Intervention: do not dispense this formulation. Compounding or an alternative preservative-free product (e.g., extemporaneous suspension from tablets or a commercial alcohol-free product) should be used. If no alternative, document risk and monitor bilirubin and glucose.
3. If the only option is the commercial product, what monitoring and safeguards would you put in place?
Read the worked answer
Obtain informed consent from parents, document the risk-benefit. Monitor total and direct bilirubin daily, glucose (ethanol-induced hypoglycemia), and neurological status. Keep the dose to the minimum effective duration. Consider phototherapy if bilirubin rises. Coordinate with neonatology. Report the excipient exposure in the medical record and consider an adverse drug reaction report if any sign of toxicity.